FDA Grants Breakthrough Therapy Designation to INOVIO's INO-3107 for Recurrent Respiratory Papillomatosis
INOVIO, a biotechnology firm specializing in the development and commercialization of DNA-based therapeutics for HPV-related diseases, cancer, and infectious ailments, has recently achieved a significant milestone. The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to INO-3107, recognizing its potential as a treatment for patients battling Recurrent Respiratory Papillomatosis (RRP).
The Breakthrough Therapy designation is a specialized process aimed at expediting the development and evaluation of drug candidates intended to address severe or life-threatening conditions. It is reserved for those candidates that demonstrate promising initial clinical evidence of substantial improvement over existing therapies in addressing significant clinical endpoints.
This development marks a crucial step forward for INO-3107, underscoring its status as a pioneering DNA medicine candidate with the potential to significantly enhance the quality of life for individuals affected by RRP. INO-3107 is an investigational DNA medicine designed to trigger a precise T cell response targeted against HPV-6 and HPV-11, which are responsible for causing RRP and other HPV-related diseases.
The basis for the Breakthrough Therapy designation stems from data collected during INOVIO's Phase 1/2 open-label, multicenter trial assessing INO-3107's safety, tolerability, immunogenicity, and efficacy in patients dealing with HPV-6 and/or HPV-11-related RRP (NCT:04398433). The trial revealed compelling results, with 81.3% of patients experiencing a reduction in surgical interventions within the year following INO-3107 administration. Notably, 28.1% of patients required no surgical intervention during or after the dosing period. This is a significant improvement compared to the median of 4 surgeries (ranging from 2 to 8) that patients underwent in the year preceding dosing. After receiving INO-3107, there was a median decrease of 3 surgical interventions. It is important to note that surgeries performed during the dosing window were considered in the efficacy assessment.
INO-3107 represents a promising clinical-stage DNA medicine candidate developed by INOVIO for the potential treatment of RRP. Its mechanism of action involves stimulating a targeted T cell response against HPV-6 and HPV-11, two primary HPV types responsible for RRP and related conditions. These specialized T cells are engineered to identify and eliminate infected cells, with the ultimate goal of preventing or slowing the growth of new papillomas.
